Make U.S. Healthcare Competitive
By Making U.S. Healthcare Competitive, We Can End Our Dependence on China, Stop Dangerous Fake Chinese Counterfeit Drugs, And Save American Lives
Competitive U.S. Healthcare Will End American Dependence on China
Around 80% “of the basic components used in U.S. drugs” come from China and India. According to a recent report from The White House, even many of the drugs that are imported to America from India and Europe are reliant on Chinese supply chains. Chinese biotech companies have supplied as much as 90 percent of the antibiotics, vitamin C, ibuprofen and hydrocortisone in the United States.
This vulnerability is only continuing to grow worse. Since just 2020, US imports of Chinese pharmaceuticals have increased by 485 percent. We must strengthen the U.S. biotech industry so that we are no longer dependent on an adversary for life-saving drugs.
Competitive U.S. Healthcare Means Stopping Dangerous and Fake Chinese Counterfeit Drugs
According to data recently released by the Centers for Disease Control and Prevention, drug overdoses hit a record high in 2022. Fentanyl overdoses have now become the leading cause of death for Americans ages 18 to 45. Law enforcement officials have warned that importing more foreign drugs could significantly raise the risk of Americans receiving fake counterfeit medications with dangerous ingredients like fentanyl. Supporting a competitive U.S. biotech industry and cracking down on dangerous and fake counterfeit drugs will save American lives.
Competitive U.S. Healthcare Will Keep America Safe
China understands that dominating the biotech industry is key to winning the 21st century. That’s why they are currently engaged in a 10-year strategic plan to become the global pharmaceutical leader, stealing over $2.4 trillion in U.S. intellectual property (IP) in their mission to surpass the United States. The best way to put American interests first is to support a strong and competitive American biotech industry that can stay ahead of China.